Loading...

APUS APIMEDS PHARMACEUTICALS US INC Capital Structure Changes 8-K Filing

PMDS

PS

APIMEDS PHARMACEUTICALS US INC

(APUS)

2025 8-K

New CEO Appointment

Settlement Agreement

Delisting Notice

Filings Delay Notification

Stockholder Consent Nullified

Board Changes Invalidated

Board Restructuring

Stock Split Announcement

Director Resignations

Merger Amendment Notice

Merger Agreement

CEO Salary Increase

Bylaw Amendment

Investor Meetings

Debt Restructuring

External Links:

On May 16, 2025, Apimeds Pharmaceuticals US, Inc. amended the maturity dates of three promissory notes totaling $500,000, extending their due dates to May 19, 2026.

AI Assistant

APIMEDS PHARMACEUTICALS US INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.